Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer

E. S. Casper, R. J. Gralla, D. P. Kelsen, R. B. Natale, P. Sordillo, A. Houghton

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

It has been reported that AMSA has antitumor activity in several human malignancies including two minor regressions in four patients with adenocarcinoma of the lung. The present study was conducted in patients having a good performance status. One third of these patients had received no prior chemotherapy. Toxicity, primarily leukopenia, did occur but no major objective responses were seen among the 22 evaluable patients. Eighteen of the patients had adenocarcinoma. At 95% confidence limits, the predicted true major response rate is <16% for patients with adenocarcinoma of the lung. We have not seen a significant difference in response rate among the subclassifications of non-small cell bronchogenic carcinoma in previous studies at this institution. Including all 22 patients, the predicted response rate of AMSA is <14% (P=0.05) for patients with non-small cell lung cancer. We conclude that AMSA, in the dose and schedule given to this population of patients, is not active as a single agent in the treatment of non-small cell carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)345-347
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number2-3
StatePublished - Dec 1 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Casper, E. S., Gralla, R. J., Kelsen, D. P., Natale, R. B., Sordillo, P., & Houghton, A. (1980). Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer. Cancer Treatment Reports, 64(2-3), 345-347.